GSK3B and central nervous system cancer: The upregulated YTHDF2 binds to the mRNA of the negative regulatory factors APC and GSK3β in the Wnt-β-Catenin pathway that are modified by m6A, promoting their degradation and thereby activating the Wnt-β-Catenin pathway, ultimately promoting glioma migration, invasion, and EMT.